Publication:
Bone marrow transplantation in Ramathibodi hospital: Progress report

dc.contributor.authorS. Jootaren_US
dc.contributor.authorS. Chuncharuneeen_US
dc.contributor.authorA. Ungkanonten_US
dc.contributor.authorW. Tanapothiwiruten_US
dc.contributor.authorP. Chiewsilpen_US
dc.contributor.otherMahidol Universityen_US
dc.date.accessioned2018-08-10T08:45:10Z
dc.date.available2018-08-10T08:45:10Z
dc.date.issued1992-12-01en_US
dc.description.abstractBone marrow transplantation has become the accepted treatment for several hematologic disorders. We have done 3 autologous and 6 allogeneic bone marrow transplantations at Ramathibodi Hospital since July 1989 in patients with acute lymphoblastic leukemia, acute non-lymphocytic leukemia, chronic myeloid leukemia, non-Hodgkin's lymphoma and severe aplastic anemia. Only one patient with aplastic anemia had late graft rejection, but the rest of them engrafted and did well during the median follow up period of 317 days (range: 39 to 962 days) post transplantation. None of the allogeneic BMT had graft-versus-host dlsease. We use cyclosporin and short course methotrexate for post transplantation immunosuppression.en_US
dc.identifier.citationAsian Pacific Journal of Allergy and Immunology. Vol.10, No.2 (1992), 117-122en_US
dc.identifier.issn0125877Xen_US
dc.identifier.other2-s2.0-0026991604en_US
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/20.500.14594/22292
dc.rightsMahidol Universityen_US
dc.rights.holderSCOPUSen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=0026991604&origin=inwarden_US
dc.subjectImmunology and Microbiologyen_US
dc.subjectMedicineen_US
dc.titleBone marrow transplantation in Ramathibodi hospital: Progress reporten_US
dc.typeArticleen_US
dspace.entity.typePublication
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=0026991604&origin=inwarden_US

Files

Collections